Search Browse Earnings

Fulcrum Therapeutics, Inc. — SlamSEC

Fulcrum Therapeutics, Inc.

Nasdaq:FULC

Pharmaceutical Preparations·CAMBRIDGE, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$80.0M

+2752.0% YoY

FY 2025

Adj. EBITDA

-$20.3M

-25.4% margin

FY 2025

Net Income

-$9.7M

-12.2% margin

FY 2025

EPS (Diluted)

-$0.16

FY 2025

Stock Price

$7.75

-5.0%

2026-03-09

52W Range

$2.31 – $15.74

P/E Ratio

-48.4x

Market Cap

$516.2M

Cash

$58.2M

FY 2025

Total Debt

—

Net Cash

$58.2M

FY 2025

Enterprise Value

$457.9M

Debt / EBITDA

2.9x

FY 2025

EV / EBITDA

-22.6x

Employees

—